Generate Biomedicines

Generate Biomedicines is not a fund but a venture-backed operating company. Capital allocation decisions sit with CEO Mike Nally and the executive team, overseen by a board that includes Flagship Pioneering representatives. The firm raised $273 million in its most recent Series C round, with Amgen and NVentures participating (per the firm, September 2023).

Generate uses its proprietary Chroma diffusion model to design protein sequences and conformations computationally, selecting targets based on predicted binding affinity, developability, and novelty. Targets are sourced internally from platform output rather than in-licensed from external biotechs. The firm prioritizes oncology and infectious disease for its wholly-owned pipeline.

Generate was founded inside Flagship Pioneering's incubator in 2018 by Molly Gibson and Flagship's Noubar Afeyan. Flagship provided the initial capital and institutional scaffolding. Generate now operates as an independent company with its own CEO and board, though Flagship maintains a board presence and the two firms share a geographic nexus in the Boston area.

Yes. Generate has publicly disclosed multi-target collaboration agreements with Amgen and Novartis. The Amgen deal, announced in January 2022, covers five clinical targets and carries up to $1.9 billion in total milestone payments plus royalties (per Amgen, January 2022). The Novartis collaboration, announced in 2023, focuses on protein-based therapeutics across multiple disease areas (per Novartis, 2023).

Generate operates as a platform biotech company. It raises venture equity rounds rather than managing outside GP-style commitments, and it uses those proceeds to fund both internal drug R&D and platform development. Its partnership agreements with large pharma companies produce milestone and royalty revenue streams that support ongoing operations.

Generate itself is a company raising venture capital, not an investor deploying capital into other entities. Its VC backers — including Flagship Pioneering, Amgen, NVentures, and MAPS Capital — target early-to-growth-stage biotech and platform companies, with Flagship typically creating and seeding its portfolio companies at inception.

Generate's Chroma model applies diffusion-based generative AI (the same underlying architecture family as image generators like DALL-E) to protein sequence and structure prediction. The firm claims its model generates novel proteins not found in natural evolutionary databases, targeting de novo antibodies and peptides. Unlike screening-based AI drug discovery companies, Generate emphasizes programmable generation rather than candidate identification from existing libraries.